Swiss National Bank Reduces Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Swiss National Bank lessened its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 2.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 588,400 shares of the biotechnology company's stock after selling 15,400 shares during the quarter. Swiss National Bank owned approximately 0.31% of BioMarin Pharmaceutical worth $56,734,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. KB Financial Partners LLC increased its holdings in BioMarin Pharmaceutical by 51.3% during the 3rd quarter. KB Financial Partners LLC now owns 348 shares of the biotechnology company's stock worth $31,000 after purchasing an additional 118 shares during the period. Lindbrook Capital LLC lifted its holdings in shares of BioMarin Pharmaceutical by 259.8% in the 4th quarter. Lindbrook Capital LLC now owns 385 shares of the biotechnology company's stock valued at $37,000 after buying an additional 278 shares during the period. Castleview Partners LLC acquired a new stake in shares of BioMarin Pharmaceutical in the 3rd quarter valued at approximately $35,000. Allworth Financial LP lifted its holdings in shares of BioMarin Pharmaceutical by 54.9% in the 4th quarter. Allworth Financial LP now owns 604 shares of the biotechnology company's stock valued at $58,000 after buying an additional 214 shares during the period. Finally, Headlands Technologies LLC lifted its holdings in shares of BioMarin Pharmaceutical by 950.0% in the 4th quarter. Headlands Technologies LLC now owns 1,281 shares of the biotechnology company's stock valued at $124,000 after buying an additional 1,159 shares during the period. Hedge funds and other institutional investors own 98.71% of the company's stock.

BioMarin Pharmaceutical Stock Performance

BioMarin Pharmaceutical stock traded down $0.34 on Monday, hitting $82.10. The company's stock had a trading volume of 882,547 shares, compared to its average volume of 1,458,392. BioMarin Pharmaceutical Inc. has a one year low of $76.02 and a one year high of $99.56. The company has a quick ratio of 1.70, a current ratio of 2.74 and a debt-to-equity ratio of 0.12. The company has a fifty day moving average price of $86.89 and a 200-day moving average price of $89.02. The firm has a market cap of $15.59 billion, a P/E ratio of 77.05, a price-to-earnings-growth ratio of 1.30 and a beta of 0.34.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its quarterly earnings data on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.05. The business had revenue of $646.21 million during the quarter, compared to the consensus estimate of $639.53 million. BioMarin Pharmaceutical had a return on equity of 5.34% and a net margin of 8.31%. BioMarin Pharmaceutical's quarterly revenue was up 20.2% on a year-over-year basis. During the same period last year, the company earned $0.11 earnings per share. On average, equities analysts anticipate that BioMarin Pharmaceutical Inc. will post 1.98 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on BMRN. Canaccord Genuity Group reduced their price objective on BioMarin Pharmaceutical from $91.00 to $89.00 and set a "hold" rating for the company in a report on Friday, April 26th. Cantor Fitzgerald restated an "overweight" rating and set a $110.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, April 25th. Royal Bank of Canada reissued a "sector perform" rating and set a $100.00 price target on shares of BioMarin Pharmaceutical in a report on Friday, February 23rd. Piper Sandler decreased their price objective on shares of BioMarin Pharmaceutical from $115.00 to $107.00 and set an "overweight" rating for the company in a report on Friday, February 23rd. Finally, Scotiabank boosted their target price on BioMarin Pharmaceutical from $83.00 to $85.00 and gave the stock a "sector perform" rating in a report on Thursday, April 25th. Seven research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $107.50.

Insider Buying and Selling

In related news, insider Henry J. Fuchs sold 35,341 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $85.18, for a total transaction of $3,010,346.38. Following the completion of the transaction, the insider now directly owns 212,117 shares in the company, valued at $18,068,126.06. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, EVP Jeffrey Robert Ajer sold 4,000 shares of the business's stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $87.07, for a total transaction of $348,280.00. Following the transaction, the executive vice president now directly owns 94,047 shares of the company's stock, valued at approximately $8,188,672.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Henry J. Fuchs sold 35,341 shares of BioMarin Pharmaceutical stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $85.18, for a total transaction of $3,010,346.38. Following the completion of the sale, the insider now owns 212,117 shares of the company's stock, valued at approximately $18,068,126.06. The disclosure for this sale can be found here. Over the last three months, insiders sold 105,079 shares of company stock worth $9,220,236. 1.85% of the stock is owned by corporate insiders.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.